A patent shows competitors the invention, not the years of development behind it.
In biotech, years of value can be built through experiments that failed, assays that were refined, manufacturing problems that were solved and data that helped the team understand what actually works and why it works.
That knowledge may never appear in a patent. In some cases, it should not.
A strong IP strategy therefore goes beyond deciding what to patent. It also determines which knowledge should remain confidential and how patents, know-how and trade secrets can strengthen each other.
A patent can protect the invention and create room for investment, partnerships and growth.
But the accumulated learning behind that invention can be just as difficult for competitors to reproduce.
A strong biotech IP strategy requires careful choices between patenting and confidentiality. Feel free to reach out if you would like to explore those choices.
